Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
6 "So Yeon Oh"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Differential Efficacy of Alpelisib by PIK3CA Mutation Site in Head and Neck Squamous Cell Carcinoma: An Analysis from the KCSG HN 15-16 TRIUMPH Trial
Kyoo Hyun Kim, Shinwon Hwang, Min Kyoung Kim, Keon-Uk Park, Tak Yun, Keun-Wook Lee, Joo Hang Kim, Bhumsuk Keam, Byoung Chul Cho, So Yeon Oh, Sang Hee Cho, Sangwoo Kim, Sung-Bae Kim, Min Hee Hong, Hye Ryun Kim
Received December 11, 2024  Accepted January 27, 2025  Published online January 31, 2025  
DOI: https://doi.org/10.4143/crt.2024.1195    [Accepted]
AbstractAbstract PDF
Purpose
The TRIUMPH trial was a biomarker-driven umbrella trial for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). This analysis focuses on the PIK3CAɑ inhibitor alpelisib (arm 1) in patients with phosphoinositide 3-kinase (PI3K) pathway alterations.
Materials and Methods
Patients with PI3K pathway altered tumors were enrolled in the alpelisib arm of the TRIUMPH study. We conducted a detailed analysis of the correlation between PI3K pathway mutations and treatment outcomes including disease control rate (DCR), overall survival (OS), and progression-free survival (PFS).
Results
From Oct 2017 and Aug 2020, 203 were enrolled, with 42 treated with alpelisib. Response evaluation was possible for 33 patients. Genomic profiles revealed PIK3CA amplifications in 26.2%, and point mutations in E542K (26.2%), E545K (23.8%), and H1047R (9.5%). Neither PIK3CA amplification nor co-occurring TP53 mutations had a notable influence on alpelisib response or survival outcomes. Although the overall response rates were similar between helical domain mutations (E542, E545) and kinase domain mutations (H1047), patients with H1047 mutations exhibited significantly poorer PFS compared to those with non-H1047 PIK3CA alterations (1.6 vs. 7.3 months, p=0.017). OS in patients with H1047 kinase domain mutations showed a trend toward being shorter compared to others, though this difference did not reach statistical significance.
Conclusion
Alpelisib showed differential efficacy based on PI3K pathway alterations in patients with R/M HNSCC and was well-tolerated. These findings suggest the usefulness of NGS testing-based decision-making when using the targeted agents in R/M HNSCC. We need to confirm results in larger cohorts.
  • 213 View
  • 21 Download
Close layer
A Prospective, Single-Cohort, Open, Multi-Center, Observational Study of Sublingual Fentanyl for Breakthrough Cancer Pain: Effectiveness, Safety, and Tolerability in Korean Cancer Patients
Youn Seon Choi, Su-Jin Koh, Woo Kyun Bae, Se Hyung Kim, Seong Hoon Shin, So Yeon Oh, Sang Byung Bae, Yaewon Yang, Eun-Kee Song, Yoon Young Cho, Pyung Bok Lee, Ho-Suk Oh, MinYoung Lee, Jin Seok Ahn
Received June 13, 2024  Accepted December 24, 2024  Published online December 26, 2024  
DOI: https://doi.org/10.4143/crt.2024.557    [Accepted]
AbstractAbstract PDF
Purpose
Fentanyl, a highly lipophilic opioid, was developed as a sublingual fentanyl tablet (SFT) for the management of breakthrough cancer pain (BTcP), and its efficacy and safety were confirmed in a randomized, controlled study. We investigated the effectiveness and safety of SFT administered to alleviate BTcP in a real-world setting.
Materials and Methods
In this prospective, open, single-cohort study, conducted in 13 referral hospitals in South Korea, opioid-tolerant cancer patients receiving around-the-clock opioids for persistent cancer pain were enrolled if the individual had BTcP ≥ 1 episode/day during the preceding week. The primary outcome was the SFT titration success rate.
Results
Among 113 patients evaluated for effectiveness, 103 patients (91.2%) had a successful titration of SFT, with an effective dose range between 100 µg and 400 µg. The most frequent dose was 100 µg, administered to 65.0%, 72.1%, and 81.8% of the patients at Week 1, 4, and 12, respectively. The proportion of patients achieving the personalized pain goal assessed in the first week was 75.2%. The mean change in pain intensity measured with a numeric rating scale at 30 and 60 minutes after taking SFT was -2.57 and -3.62, respectively (p<0.0001 for both). The incidence rate of adverse events related to SFT among 133 patients included for safety evaluation was 9.0% (12/133), which included vomiting (3.0%), nausea (2.3%), and headache (1.5%).
Conclusion
In a real-world setting, SFT provides rapid and effective analgesia in BTcP, even at the lowest dose (100 μg), and the safety profile was acceptable.
  • 380 View
  • 49 Download
Close layer
General
A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy
Young-Woong Won, Jin-Hyoung Kang, Jung Hye Kwon, Dong-Hoe Koo, Jung Hun Kang, Chi Hoon Maeng, Hee Kyung Ahn, Sung Yong Oh, Dae-Won Lee, Joohyuk Sohn, So Yeon Oh, Kyung Hee Lee, Su-Jin Koh, Keun Seok Lee, Chan-Kyu Kim, Ji-Yeon Kim, Jun Ho Ji, Sung-Bae Kim, Joo Young Ha, Ho Young Kim
Cancer Res Treat. 2023;55(4):1096-1103.   Published online April 7, 2023
DOI: https://doi.org/10.4143/crt.2022.1565
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Several previous studies and case reports have reported ethanol-induced symptoms in patients receiving anticancer drugs containing ethanol. Most docetaxel formulations contain ethanol as a solvent. However, there are insufficient data on ethanol-induced symptoms when docetaxel-containing ethanol is administered. The primary purpose of this study was to investigate the frequency and pattern of ethanol-induced symptoms during and after docetaxel administration. The secondary purpose was to explore the risk factors for ethanol-induced symptoms.
Materials and Methods
This was a prospective, multicenter, observational study. The participants filled out ethanol-induced symptom questionnaire on the day of chemotherapy and the following day.
Results
Data from 451 patients were analyzed. The overall occurrence rate of ethanol-induced symptoms was 44.3% (200/451 patients). The occurrence rate of facial flushing was highest at 19.7% (89/451 patients), followed by nausea in 18.2% (82/451 patients), and dizziness in 17.5% (79/451 patients). Although infrequent, unsteady walking and impaired balance occurred in 4.2% and 3.3% of patients, respectively. Female sex, presence of underlying disease, younger age, docetaxel dose, and docetaxel-containing ethanol amount were significantly associated with the occurrence of ethanol-induced symptoms.
Conclusion
The occurrence of ethanol-induced symptoms was not low in patients receiving docetaxel-containing ethanol. Physicians need to pay more attention to the occurrence of ethanol-induced symptoms and prescribe ethanol-free or low-ethanol-containing formulations to high-risk patients.

Citations

Citations to this article as recorded by  
  • Evaluation of self-assembling properties of paclitaxel-biotin conjugates
    Dmitry V. Beigulenko, Anna Yu. Belyaeva, Ekaterina S. Kazakova, Maria M. Antonova, Aleksander S. Peregudov, Aleksey A. Nikitin, Tatyana S. Kovshova, Yulia V. Ermolenko, Konstantin A. Kochetkov
    Nano-Structures & Nano-Objects.2024; 40: 101375.     CrossRef
  • 3,548 View
  • 218 Download
  • 1 Crossref
Close layer
Palliative Medicine
Safety, Efficacy, and Patient Satisfaction with Initial Peripherally Inserted Central Catheters Compared with Usual Intravenous Access in Terminally Ill Cancer Patients: A Randomized Phase II Study
Eun Ju Park, Kwonoh Park, Jae-Joon Kim, Sang-Bo Oh, Ki Sun Jung, So Yeon Oh, Yun Jeong Hong, Jin Hyeok Kim, Joo Yeon Jang, Ung-Bae Jeon
Cancer Res Treat. 2021;53(3):881-888.   Published online December 22, 2020
DOI: https://doi.org/10.4143/crt.2020.1008
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to investigate whether routine insertion of peripherally inserted central catheter (PICC) at admission to a hospice-palliative care (HPC) unit is acceptable in terms of safety and efficacy and whether it results in superior patient satisfaction compared to usual intravenous (IV) access.
Materials and Methods
Terminally ill cancer patients were randomly assigned to two arms: routine PICC access and usual IV access arm. The primary endpoint was IV maintenance success rate, defined as the rate of functional IV maintenance until the intended time (discharge, transfer, or death).
Results
A total of 66 terminally ill cancer patients were enrolled and randomized to study arms. Among them, 57 patients (routine PICC, 29; usual IV, 28) were analyzed. In the routine PICC arm, mean time to PICC was 0.84 days (range, 0 to 3 days), 27 patients maintained PICC with function until the intended time. In the usual IV arm, 11 patients maintained peripheral IV access until the intended time, and 15 patients underwent PICC insertion. The IV maintenance success rate in the routine PICC arm (27/29, 93.1%) was similar to that in the usual IV arm (26/28, 92.8%, p=0.958). Patient satisfaction at day 5 was better in the routine PICC arm (97%, ‘a little comfort’ or ‘much comfort’) compared with the usual IV arm (21%) (p <0.001).
Conclusion
Routine PICC insertion in terminally ill cancer patients was comparable in safety and efficacy and resulted in superior satisfaction compared with usual IV access. Thus, routine PICC insertion could be considered at admission to the HPC unit.

Citations

Citations to this article as recorded by  
  • A Phase II Study About Efficacy and Safety of the Continuous IntraVenous Infusion of Ketamine as Adjuvant to Opioids in Terminally Ill Cancer Patients With Refractory Cancer Pain (CIVIK Trial)
    Kwonoh Park, Jae-Joon Kim, Sang-Bo Oh, So Yeon Oh, Yun Jeong Hong, Seo-jun Kim, Eun-Ju Park, Nayeon Choi, Seon-Hi Shin, Sungeun Kim, Heejung Ko
    American Journal of Hospice and Palliative Medicine®.2025; 42(3): 244.     CrossRef
  • Implementation of Tunneled Peripherally Inserted Central Catheters Placement in Cancer Patients: A Randomized Multicenter Study
    Yuan Sheng, Li-Hong Yang, Yan Wu, Wei Gao, Sheng-Yi Dongye
    Clinical Nursing Research.2024; 33(1): 19.     CrossRef
  • The Use of a High Flow PICC Catheter for Stem Cell and Lymphocyte Apheresis: The Initial Experience of a Pediatric Oncology Center in Brazil
    Vilani Kremer, Andréia Rheinheimer, Ana Luiza Rodrigues, Andressa Taborda, Robson Coelho, Antonella Zanette
    Journal of Pediatric Surgery.2024; 59(8): 1600.     CrossRef
  • Analysis of Risk Factors for Peripherally Inserted Central Venous Catheter-Associated Bloodstream Infection
    Sungho Lee, Kwanhoon Park, Kang Yoon Lee, Dongbeen Choi, Ji Young Jang
    Journal of Acute Care Surgery.2024; 14(1): 9.     CrossRef
  • Central venous access device terminologies, complications, and reason for removal in oncology: a scoping review
    Kerrie Curtis, Karla Gough, Meinir Krishnasamy, Elena Tarasenko, Geoff Hill, Samantha Keogh
    BMC Cancer.2024;[Epub]     CrossRef
  • Use of peripherally inserted central venous catheters and midline catheters for palliative care in patients with cancer: a systematic review
    Eva Gravdahl, Dagny Faksvåg Haugen, Olav Magnus Fredheim
    Supportive Care in Cancer.2024;[Epub]     CrossRef
  • Machine Learning Predicts Peripherally Inserted Central Catheters-Related Deep Vein Thrombosis Using Patient Features and Catheterization Technology Features
    Yuan Sheng, Wei Gao
    Clinical Nursing Research.2024; 33(6): 460.     CrossRef
  • Safety of Cryopreserved Stem Cell Infusion through a Peripherally Inserted Central Venous Catheter
    Sławomir Milczarek, Piotr Kulig, Alina Zuchmańska, Bartłomiej Baumert, Bogumiła Osękowska, Anna Bielikowicz, Ewa Wilk-Milczarek, Bogusław Machaliński
    Cancers.2023; 15(4): 1338.     CrossRef
  • Use and safety of peripherally inserted central catheters and midline catheters in palliative care cancer patients: a retrospective review
    Eva Gravdahl, Siri Steine, Knut Magne Augestad, Olav Magnus Fredheim
    Supportive Care in Cancer.2023;[Epub]     CrossRef
  • Complications of Central Venous Access Devices Used in Palliative Care Settings for Terminally Ill Cancer Patients: A Systematic Review and Meta-Analysis
    Clement Chun-Him Wong, Horace Cheuk-Wai Choi, Victor Ho-Fun Lee
    Cancers.2023; 15(19): 4712.     CrossRef
  • Safety and Efficacy of Peripherally Inserted Central Catheter Placement by Surgical Intensivist–Led Vascular Access Team
    Byunghyuk Yu, Jihoon Hong
    Vascular Specialist International.2022;[Epub]     CrossRef
  • Effects of parenteral nutrition and hydration on survival in advanced cancer patients with malignant bowel obstruction: secondary analysis of a multicenter prospective cohort study
    Sayaka Arakawa, Koji Amano, Shunsuke Oyamada, Isseki Maeda, Hiroto Ishiki, Tomofumi Miura, Yutaka Hatano, Akemi Shirado Naito, Mamiko Sato, Tetsuya Ito, Kazuhiro Kosugi, Satoshi Miyake, Tatsuya Morita, Masanori Mori, Satoshi Inoue, Naosuke Yokomichi, Keng
    Supportive Care in Cancer.2021; 29(12): 7541.     CrossRef
  • Catheter-related bloodstream infection associated with multiple insertions of the peripherally inserted central catheter in patients with hematological disorders
    Yoshinori Hashimoto, Rina Hosoda, Hiromi Omura, Takayuki Tanaka
    Scientific Reports.2021;[Epub]     CrossRef
  • 6,576 View
  • 202 Download
  • 13 Crossref
Close layer
Validity and Reliability of Korean Version of Simplified Nutritional Appetite Questionnaire in Patients with Advanced Cancer: A Multicenter, Longitudinal Study
So Yeon Oh, Su-Jin Koh, Ji Yeon Baek, Kyung A Kwon, Hei-Cheul Jeung, Kyung Hee Lee, Young-Woong Won, Hyun Jung Lee
Cancer Res Treat. 2019;51(4):1612-1619.   Published online April 12, 2019
DOI: https://doi.org/10.4143/crt.2018.505
AbstractAbstract PDFPubReaderePub
Purpose
Malnutrition and a loss of muscle mass are frequent in cancer patients and have a negative effect on clinical outcome. Nutrition risk screening aims to increase awareness and allow early recognition and treatment of cancer cachexia. Therefore, screenings should be brief, inexpensive, highly sensitive, and have good specificity. Simplified Nutritional Appetite Questionnaire (SNAQ) is a simple screening tool including four questions, and validated to predict weight loss within 6 months in community-dwelling adults and nursing home residents. Our study aimed to translate the SNAQ into Korean, and to assess the validity and reliability of the translated screening tool in advanced cancer patients.
Materials and Methods
The SNAQ was translated into Korean according to linguistic validation. The internal consistency of the SNAQ was evaluated by Cronbach’s alpha coefficient. Test-retest reliability was evaluated using the intraclass correlation coefficient. Concurrent validity was evaluated by measuring the Pearson’s correlation coefficient between the SNAQ and Mini-Nutritional Assessment (MNA) and Patient-Generated Subjective Global Assessment (PG-SGA).
Results
In the 194 patients included in full analysis set, cancer stage was predominantly metastatic (98.5%), the mean age was 60 years (range, 23 to 81 years), and the mean body mass index was 24 kg/m2 (range, 15.6 to 39.6 kg/m2). According to MNA score ≤ 11, 57 patients (29.4%) were malnourished. The mean score (±standard deviation) of the Korean version of the SNAQ was 13.8±2.5 with a range of 6-19. Cronbach’s alpha coefficient was 0.737, and intraclass correlation coefficient was 0.869. The SNAQ was moderately correlated with MNA (r=0.404, p < 0.001) and PG-SGA (r=–0.530, p < 0.001). A significant weight loss of > 5% of the original bodyweightwithin 6 months occurred in 46 of the 186 patients (24.7%). SNAQ score ≤ 14 predicted > 5% weight loss with a sensitivity of 56.5% and a specificity of 44.3%.
Conclusion
The Korean version of the SNAQ had high validity and reliability. SNAQ is useful for the screening tool for advanced cancer patients. The SNAQ had a limitation to predict impending weight loss in advanced cancer patients.

Citations

Citations to this article as recorded by  
  • Demographic, clinical and psychological predictors of malnutrition among people with liver cancer
    Yumi Kim, Sung Reul Kim, Kyounghae Kim, Su Jong Yu
    European Journal of Oncology Nursing.2024; 68: 102497.     CrossRef
  • Therapeutic Potential of Combined Herbal Medicine and Electroacupuncture in Mild Cognitive Impairment Through Cytokine Modulation: An Observational Study
    Jung-Hee Jang, Hyeong Joon Jun, ChaYoung Lee, Eunjin Sohn, Ojin Kwon, Dong-Hoon Kang, Muhammad Umar, In Chul Jung, Soo-Jin Jeong
    Neuropsychiatric Disease and Treatment.2024; Volume 20: 1331.     CrossRef
  • Reliability and validity of Chinese version of the Simplified Nutritional Appetite Questionnaire (SNAQ) in community-dwelling old people
    Gaojie Feng, Xiaohong Sun, Qiumei Wang, Fei Lu, Yuanyuan Li, Yaru Zhou, Xiaohong Liu
    Geriatric Nursing.2024; 59: 351.     CrossRef
  • Malnutrition risk screening in adult oncology outpatients: An ASPEN systematic review and clinical recommendations
    Elaine B. Trujillo, Kunal C. Kadakia, Cynthia Thomson, Fang Fang Zhang, Alicia Livinski, Kim Pollard, Todd Mattox, Anne Tucker, Valaree Williams, Declan Walsh, Steven Clinton, Aaron Grossberg, Gordon Jensen, Rhone Levin, Jeannine Mills, Anurag Singh, Mere
    Journal of Parenteral and Enteral Nutrition.2024; 48(8): 874.     CrossRef
  • Assessment of nutritional status using objective and subjective methods in Greek patients with cancer
    Konstantina Vamvakari, Iliana Evangelou, Ioanna Panagiota Kalafati, Michail Kipouros, Rena I. Kosti, Arezina N. Kasti, Odysseas Androutsos
    memo - Magazine of European Medical Oncology.2023; 16(3): 200.     CrossRef
  • AIWW: a new nutrition-screening tool for the oncologic population
    Yi-Zhong Ge, Zhen-Ming Fu, Qi Zhang, Meng-Meng Song, Guo-Tian Ruan, Xi Zhang, Xiao-Wei Zhang, Xiang-Rui Li, Kang-Ping Zhang, Meng Tang, Xiao-Yue Liu, Ming Yang, Tong Liu, Hai-Lun Xie, He-Yang Zhang, Zi-Wen Wang, Chun-Lei Hu, Shi-Qi Lin, Rui Zhang, Hong-Xi
    Science China Life Sciences.2023; 66(8): 1831.     CrossRef
  • Validation of a telephone‐based administration of the simplified nutritional appetite questionnaire
    Binh Duong Thai, Jürgen M. Bauer, Annette Eidam, Jane Durga, Stefan Grund, Thomas Mross, Petra Benzinger
    Journal of Cachexia, Sarcopenia and Muscle.2023; 14(4): 1848.     CrossRef
  • Faeces from malnourished colorectal cancer patients accelerate cancer progression
    Xu Chao, Zhang Lei, Liu Hongqin, Wang Ziwei, Li Dechuan, Du Weidong, Xu Lu, Chen Haitao, Zhang Bo, Ju Haixing, Yao Qinghua
    Clinical Nutrition.2022; 41(3): 632.     CrossRef
  • Influence of cognitive function and nurse support on malnutrition risk in nursing home residents
    Annamária Pakai, Emese Havasi‐Sántha, Erzsébet Mák, Orsolya Máté, Dorina Pusztai, Noémi Fullér, Miklós Zrínyi, András Oláh
    Nursing Open.2021; 8(4): 1805.     CrossRef
  • Effectiveness of Oral Nutritional Supplements on Older People with Anorexia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Mengqi Li, Si Zhao, Shuang Wu, Xiufen Yang, Hui Feng
    Nutrients.2021; 13(3): 835.     CrossRef
  • Loss of appetite in patients with amyotrophic lateral sclerosis is associated with weight loss and anxiety/depression
    Yajun Wang, Shan Ye, Lu Chen, Lu Tang, Dongsheng Fan
    Scientific Reports.2021;[Epub]     CrossRef
  • Efficacy and Tolerability of Cyproheptadine in Poor Appetite: A Multicenter, Randomized, Double-blind, Placebo-controlled Study
    Sue Youn Kim, Jae Moon Yun, Ji-Won Lee, Young Gyu Cho, Kyung-Hwan Cho, Yong Gyu Park, Belong Cho
    Clinical Therapeutics.2021; 43(10): 1757.     CrossRef
  • Development of Korean Frailty Index for Primary Care (KFI-PC) and Its Criterion Validity
    Chang Won Won, Yunhwan Lee, Seoyoon Lee, Miji Kim
    Annals of Geriatric Medicine and Research.2020; 24(2): 125.     CrossRef
  • The Simplified Nutritional Appetite Questionnaire (SNAQ) as a Screening Tool for Risk of Malnutrition: Optimal Cutoff, Factor Structure, and Validation in Healthy Community-Dwelling Older Adults
    Sabrina Lau, Kalene Pek, Justin Chew, Jun Pei Lim, Noor Hafizah Ismail, Yew Yoong Ding, Matteo Cesari, Wee Shiong Lim
    Nutrients.2020; 12(9): 2885.     CrossRef
  • 8,127 View
  • 205 Download
  • 15 Web of Science
  • 14 Crossref
Close layer
Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer
Jin Won Kim, Jong Gwang Kim, Byung Woog Kang, Ik-Joo Chung, Young Seon Hong, Tae-You Kim, Hong Suk Song, Kyung Hee Lee, Dae Young Zang, Yoon Ho Ko, Eun-Kee Song, Jin Ho Baek, Dong‐Hoe Koo, So Yeon Oh, Hana Cho, Keun-Wook Lee
Cancer Res Treat. 2019;51(1):223-239.   Published online October 19, 2018
DOI: https://doi.org/10.4143/crt.2018.073
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to evaluate chemotherapy patterns and changes in quality of life (QOL) during first-line palliative chemotherapy for Korean patients with unresectable or metastatic/recurrent gastric cancer (GC).
Materials and Methods
Thiswas a non-interventional, multi-center, prospective, observational study of 527 patients in Korea. QOL assessments were conducted using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires (QLQ)-C30 and QLQ-STO22 every 3 months over a 12-month period during first-line palliative chemotherapy. The specific chemotherapy regimens were selected by individual clinicians.
Results
Most patients (93.2%) received combination chemotherapy (mainly fluoropyrimidine plus platinum) as their first-line palliative chemotherapy. The median progression-free survival and overall survival were 8.2 and 14.8 months, respectively. Overall, “a little” changes (differences of 5-10 points from baseline)were observed in some of the functioning or symptom scales; none of the QOL scales showed either “moderate” or “very much” change (i.e., ≥ 11 point difference from baseline). When examining the best change in each QOL domain from baseline, scales related to some aspects of functioning, global health status/QOL, and most symptoms revealed significant improvements (p < 0.05). Throughout the course of first-line palliative chemotherapy, most patients’ QOL was maintained to a similar degree, regardless of their actual response to chemotherapy.
Conclusion
This observational study provides important information on the chemotherapy patterns and QOL changes in Korean patientswith advanced GC. Overall, first-line palliative chemotherapy was found to maintain QOL, and most parameters showed an improvement compared with the baseline at some point during the course.

Citations

Citations to this article as recorded by  
  • Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer
    Z.A. Wainberg, P.C. Enzinger, S. Qin, K. Yamaguchi, J. Wang, X. Zhou, A. Gnanasakthy, K. Taylor, A. Yusuf, I. Majer, A. Jamotte, Y.-K. Kang
    ESMO Gastrointestinal Oncology.2024; 6: 100095.     CrossRef
  • Impact of systemic cancer treatment on quality of life and mental well-being: a comparative analysis of patients with localized and advanced cancer
    Adán Rodríguez-Gonzalez, Alberto Carmona-Bayonas, Raquel Hernandez San Gil, Patricia Cruz-Castellanos, Mónica Antoñanzas-Basa, David Lorente-Estelles, María Jose Corral, Manuel González-Moya, Oscar Alfredo Castillo-Trujillo, Emilio Esteban, Paula Jiménez-
    Clinical and Translational Oncology.2023; 25(12): 3492.     CrossRef
  • Reminiscence therapy-based care program alleviates anxiety and depression, as well as improves the quality of life in recurrent gastric cancer patients
    Xing Wu, Weiwei Zhang
    Frontiers in Psychology.2023;[Epub]     CrossRef
  • Toxicities and Quality of Life during Cancer Treatment in Advanced Solid Tumors
    Eun Mi Lee, Paula Jiménez-Fonseca, Rocio Galán-Moral, Sara Coca-Membribes, Ana Fernández-Montes, Elena Sorribes, Esmeralda García-Torralba, Laura Puntí-Brun, Mireia Gil-Raga, Juana Cano-Cano, Caterina Calderon
    Current Oncology.2023; 30(10): 9205.     CrossRef
  • Psychosocial functioning in individuals with advanced oesophago-gastric cancer: a mixed methods systematic review
    Cara Ghiglieri, Martin Dempster, Sam Wright, Lisa Graham-Wisener
    BMC Palliative Care.2023;[Epub]     CrossRef
  • Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial)
    Keun-Wook Lee, Ik-Joo Chung, Min-Hee Ryu, Young Iee Park, Byung-Ho Nam, Ho-Suk Oh, Kyung Hee Lee, Hye Sook Han, Bong-Gun Seo, Jae-Cheol Jo, Hyo Rak Lee, Jin Won Kim, Sook Ryun Park, Sang Hee Cho, Yoon-Koo Kang
    Gastric Cancer.2021; 24(1): 156.     CrossRef
  • Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial
    Kazumasa Fujitani, Kohei Shitara, Atsuo Takashima, Keisuke Koeda, Hiroki Hara, Norisuke Nakayama, Shuichi Hironaka, Kazuhiro Nishikawa, Yutaka Kimura, Kenji Amagai, Hisashi Hosaka, Yoshito Komatsu, Ken Shimada, Ryohei Kawabata, Hideki Ohdan, Yasuhiro Kode
    Gastric Cancer.2021; 24(2): 467.     CrossRef
  • Quality-of-Life Assessment in Patients Receiving Palliative Chemotherapy: Call for Action
    Maheswari Senthil
    Annals of Surgical Oncology.2021; 28(1): 7.     CrossRef
  • Impact of gastric cancer treatment on quality of life of patients
    Kerstin Schütte, Christian Schulz, Kristina Middelberg-Bisping
    Best Practice & Research Clinical Gastroenterology.2021; 50-51: 101727.     CrossRef
  • Influencing Factors and Effects of Treatment on Quality of Life in Patients With Gastric Cancer—A Systematic Review
    Sophia Kristina Rupp, Andreas Stengel
    Frontiers in Psychiatry.2021;[Epub]     CrossRef
  • Chronological changes in quality of life and body composition after gastrectomy for locally advanced gastric cancer
    Ki Bum Park, Ji Yeon Park, Seung Soo Lee, Ho Young Chung, Oh Kyoung Kwon
    Annals of Surgical Treatment and Research.2020; 98(5): 262.     CrossRef
  • Viennese risk prediction score for Advanced Gastroesophageal carcinoma based on Alarm Symptoms (VAGAS score): characterisation of alarm symptoms in advanced gastro-oesophageal cancer and its correlation with outcome
    Hannah Christina Puhr, Eleonore Pablik, Anna Sophie Berghoff, Gerd Jomrich, Sebastian Friedrich Schoppmann, Matthias Preusser, Aysegül Ilhan-Mutlu
    ESMO Open.2020; 5(2): e000623.     CrossRef
  • 11,451 View
  • 235 Download
  • 12 Web of Science
  • 12 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP